NCT05738980 is a NA clinical trial of Autologous RAK cells in Hepatocellular Carcinoma, sponsored by Beijing Hospital.

Who is sponsoring NCT05738980?

NCT05738980 is sponsored by Beijing Hospital.

What drugs are being tested in NCT05738980?

Interventions in NCT05738980: Autologous RAK cells.

What condition does NCT05738980 study?

NCT05738980 studies Hepatocellular Carcinoma.

Is NCT05738980 still recruiting?

NCT05738980 is currently recruiting now. Last updated 22 February 2023.

Last reviewed 2023-02-22 · How we verify

NCT05738980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Recruiting now NA Last updated 22 February 2023

What this trial tests

NA trial testing Autologous RAK cells in Hepatocellular Carcinoma in 88 participants. Currently enrolling.

Timeline

1 February 2023

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	Beijing Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	88
Start date	1 February 2023
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Autologous RAK cells — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Beijing Hospital

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the safety and efficacy of unmodified RAK cells and anti-TIM-3 blocked autologous RAK cells in preventing postoperative recurrence of HCC by postoperative TACE therapy combined with immune cell therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L, Li Y, Tan J, Xu L, et al · · 2023 · cited 232× · PMID 37670328 · DOI 10.1186/s13045-023-01499-1
Emerging IO checkpoints in gastrointestinal oncology.
Tojjari A, Saeed A, Cavalcante L. · · 2025 · cited 3× · PMID 40777027 · DOI 10.3389/fimmu.2025.1575713

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Beijing Hospital trials

Trials by the same sponsor.

NCT07523724 — Screening and Management of Adults With Asthma and Allergic Diseases · NA · not yet recruiting
NCT07398430 — Metabolic Characteristics and Prognostic Model of Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea · not yet recruiting
NCT07295665 — External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease · not yet recruiting
NCT07143851 — Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases · not yet recruiting
NCT06955819 — GUTPROH: Probiotic-Herbal Formula for Self-Reported Constipation in Community Adults · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05738980 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Hospital
Last refreshed: 22 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05738980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing